TNF/TNFR1 signaling mediates doxorubicin-induced diaphragm weakness

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 300, Issue 2, 2011, Pages

  Gilliam, Laura A A ^a   Moylan, Jennifer S ^a   Ferreira, Leonardo F ^a   Reid, Michael B ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Cancer; Chemotherapy; Inflammation; Skeletal muscle

Indexed keywords

DOXORUBICIN; ETANERCEPT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DIAPHRAGM MUSCLE; MALE; MOUSE; MUSCLE CELL; MUSCLE WEAKNESS; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; DIAPHRAGM; DNA PRIMERS; DOXORUBICIN; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE WEAKNESS; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 79551574266     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00264.2010     Document Type: Article

References (61)

1. Adams V, Mangner N, Gasch A, Krohne C, Gielen S, Hirner S, Thierse HJ, Witt CC, Linke A, Schuler G, Labeit S. Induction of MuRF1 is essential for TNF-alpha-induced loss of muscle function in mice. J Mol Biol 384: 48-59, 2008.
2. Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 9: 52, 2008.
3. Andrade FH, Reid MB, Allen DG, Westerblad H. Effect of hydrogen peroxide and dithiothreitol on contractile function of single skeletal muscle fibres from the mouse. J Physiol 509: 565-575, 1998.
4. Arndt V, Stegmaier C, Ziegler H, Brenner H. A population-based study of the impact of specific symptoms on quality of life in women with breast cancer 1 year after diagnosis. Cancer 107: 2496-2503, 2006.
5. Azevedo LC, Janiszewski M, Pontieri V, Pedro Mde A, Bassi E, Tucci PJ, Laurindo FR. Platelet-derived exosomes from septic shock patients induce myocardial dysfunction. Crit Care 11: R120, 2007.
6. Basso SM, Caratozzolo E, Massani M, Antoniutti M, di Pinto FC, Callegari P, Bonariol L, Bassi N. Nocturnal dyspnea in a young adult male patient: a typical case of an unrecognized traumatic rupture of the diaphragm. J Trauma 56: 720, 2004.
7. Beckman JS. Oxidative damage and tyrosine nitration from peroxynitrite. Chem Res Toxicol 9: 836-844, 1996.
8. Bradley JR, Thiru S, Pober JS. Disparate localization of 55-kd and 75-kd tumor necrosis factor receptors in human endothelial cells. Am J Pathol 146: 27-32, 1995.
9. Bristol JA, Morrison TE, Kenney SC. CCAAT/enhancer binding proteins alpha and beta regulate the tumor necrosis factor receptor 1 gene promoter. Mol Immunol 46: 2706-2713, 2009.
10. Chabner BA, Ryan DP, Paz-Ares L, Garcia-Carbonero R, Calabresi P, Hardman JG, Limbird LE, Gilman AG. Goodman & Gilman's The pharmacologic Basis of Therapeutics. New York: McGraw-Hill, Medical Publishing Division, 2001.
11. Close RI. Dynamic properties of mammalian skeletal muscles. Physiol Rev 52: 129-197, 1972.
12. Conraads V. Pro-inflammatory cytokines and their receptors in chronic heart failure: do they really matter? Acta Cardiol 61: 161-168, 2006.
13. Crisafulli C, Galuppo M, Cuzzocrea S. Effects of genetic and pharmacological inhibition of TNF-alpha in the regulation of inflammation in macrophages. Pharmacol Res 60: 332-340, 2009.
14. Delgado G, Potkul RK, Treat JA, Lewandowski GS, Barter JF, Forst D, Rahman A. A phase I/II study of intraperitoneally administered doxorubicin entrapped in cardiolipin liposomes in patients with ovarian cancer. Am J Obstet Gynecol 160: 812-817; discussion 817-819, 1989.
15. Dy SM, Lorenz KA, Naeim A, Sanati H, Walling A, Asch SM. Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea. J Clin Oncol 26: 3886-3895, 2008.
16. Elbl L, Vasova I, Tomaskova I, Jedlicka F, Kral Z, Navratil M, Smardova L, Wagnerova B, Vorlicek J. Cardiopulmonary exercise testing in the evaluation of functional capacity after treatment of lymphomas in adults. Leuk Lymphoma 47: 843-851, 2006.
17. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50: 219-244, 1966.
18. Ganz PA, Bower JE. Cancer related fatigue: a focus on breast cancer and Hodgkin's disease survivors. Acta Oncol 46: 474-479, 2007.
19. Gilliam LA, Ferreira LF, Bruton JD, Moylan JS, Westerblad H, St Clair DK, Reid MB. Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle. J Appl Physiol 107: 1935-1942, 2009.
20. Gilliam LA, Moylan JS, Callahan LA, Sumandea MP, Reid MB. Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy. Muscle Nerve. In press.
21. Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 25: 386-401, 2001. (Pubitemid 34164011)
22. Glass B, Kloess M, Bentz M, Schlimok G, Berdel WE, Feller A, Trumper L, Loeffler M, Pfreundschuh M, Schmitz N. Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. Blood 107: 3058-3064, 2006.
23. Grounds MD, Davies M, Torrisi J, Shavlakadze T, White J, Hodgetts S. Silencing TNFalpha activity by using Remicade or Enbrel blocks inflammation in whole muscle grafts: an in vivo bioassay to assess the efficacy of anti-cytokine drugs in mice. Cell Tissue Res 320: 509-515, 2005. (Pubitemid 40884152)
24. Hardin BJ, Campbell KS, Smith JD, Arbogast S, Smith J, Moylan JS, Reid MB. TNF-alpha acts via TNFR1 and muscle-derived oxidants to depress myofibrillar force in murine skeletal muscle. J Appl Physiol 104: 694-699, 2008. (Pubitemid 351468797)
25. Hawari FI, Rouhani FN, Cui X, Yu ZX, Buckley C, Kaler M, Levine SJ. Release of full-length 55-kDa TNF receptor 1 in exosome-like vesicles: a mechanism for generation of soluble cytokine receptors. Proc Natl Acad Sci USA 101: 1297-1302, 2004.
26. Hernandez OM, Jones M, Guzman G, Szczesna-Cordary D. Myosin essential light chain in health and disease. Am J Physiol Heart Circ Physiol 292: H1643-H1654, 2007.
27. Hirsch A, Vander Els N, Straus DJ, Gomez EG, Leung D, Portlock CS, Yahalom J. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J Clin Oncol 14: 1297-1305, 1996.
28. Hjermstad MJ, Oldervoll L, Fossa SD, Holte H, Jacobsen AB, Loge JH. Quality of life in long-term Hodgkin's disease survivors with chronic fatigue. Eur J Cancer 42: 327-333, 2006.
29. Idriss HT, Naismith JH. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech 50: 184-195, 2000. (Pubitemid 30610095)
30. Jacobsen PB, Hann DM, Azzarello LM, Horton J, Balducci L, Lyman GH. Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manage 18: 233-242, 1999. (Pubitemid 29469701)
31. Jiang Y, Deacon R, Anthony DC, Campbell SJ. Inhibition of peripheral TNF can block the malaise associated with CNS inflammatory diseases. Neurobiol Dis 32: 125-132, 2008.
32. Johansen PB. Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse. Cancer Chemother Pharmacol 5: 267-270, 1981.
33. Jones SJ, Ledgerwood EC, Prins JB, Galbraith J, Johnson DR, Pober JS, Bradley JR. TNF recruits TRADD to the plasma membrane but not the trans-Golgi network, the principal subcellular location of TNF-R1. J Immunol 162: 1042-1048, 1999.
34. Kramer JA, Curran D, Piccart M, de Haes JC, Bruning P, Klijn J, Van Hoorebeeck I, Paridaens R. Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer 36: 1498-1506, 2000.
35. Lamb GD, Posterino GS. Effects of oxidation and reduction on contractile function in skeletal muscle fibres of the rat. J Physiol 546: 149-163, 2003.
36. Lien YC, Noel T, Liu H, Stromberg AJ, Chen KC, St Clair DK. Phospholipase C-delta1 is a critical target for tumor necrosis factor receptor-mediated protection against adriamycin-induced cardiac injury. Cancer Res 66: 4329-4338, 2006.
37. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2[-Delta Delta C(T)] Method. Methods 25: 402-408, 2001.
38. Lund MB, Kongerud J, Boe J, Nome O, Abrahamsen AF, Ihlen H, Forfang K. Cardiopulmonary sequelae after treatment for Hodgkin's disease: increased risk in females? Ann Oncol 7: 257-264, 1996.
39. Marks LB, Halperin EC, Prosnitz LR, Ross M, Vredenburgh JJ, Rosner GL, Peters W. Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes. Cancer and Leukemia Group B. Int J Radiat Oncol Biol Phys 23: 1021-1026, 1992.
40. Mazzon E, Esposito E, Di Paola R, Muia C, Crisafulli C, Genovese T, Caminiti R, Meli R, Bramanti P, Cuzzocrea S. Effect of tumour necrosis factor-alpha receptor 1 genetic deletion on carrageenan-induced acute inflammation: a comparison with etanercept. Clin Exp Immunol 153: 136-149, 2008.
41. Meeske KA, Siegel SE, Globe DR, Mack WJ, Bernstein L. Prevalence and correlates of fatigue in long-term survivors of childhood leukemia. J Clin Oncol 23: 5501-5510, 2005.
42. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol Regul Integr Comp Physiol 274: R577-R595, 1998.
43. Moncman CL, Wang K. Nebulette: a 107 kD nebulin-like protein in cardiac muscle. Cell Motil Cytoskeleton 32: 205-225, 1995.
44. Moore AJ, Moxham J, Polkey MI. Diaphragm weakness as a cause of breathlessness after anatomically distant surgery. Thorax 60: 786-787, 2005.
45. Morsi MI, Hussein AE, Mostafa M, El-Abd E, El-Moneim NA. Evaluation of tumour necrosis factor-alpha, soluble P-selectin, gamma-glutamyl transferase, glutathione S-transferase-pi and alpha-fetoprotein in patients with hepatocellular carcinoma before and during chemotherapy. Br J Biomed Sci 63: 74-78, 2006.
46. Mukherjee S, Banerjee SK, Maulik M, Dinda AK, Talwar KK, Maulik SK. Protection against acute adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF-alpha expression. BMC Pharmacol 3: 16, 2003.
47. Newton RC, Solomon KA, Covington MB, Decicco CP, Haley PJ, Friedman SM, Vaddi K. Biology of TACE inhibition. Ann Rheum Dis 60, Suppl 3: iii25-iii32, 2001.
48. Paulin E, Yamaguti WP, Chammas MC, Shibao S, Stelmach R, Cukier A, Carvalho CR. Influence of diaphragmatic mobility on exercise tolerance and dyspnea in patients with COPD. Respir Med 101: 2113-2118, 2007.
49. Piscitelli SC, Rodvold KA, Rushing DA, Tewksbury DA. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther 53: 555-561, 1993.
50. Ripamonti C. Management of dyspnea in advanced cancer patients. Support Care Cancer 7: 233-243, 1999.
51. Roychowdhury DF, Hayden A, Liepa AM. Health-related quality-of-life parameters as independent prognostic factors in advanced or metastatic bladder cancer. J Clin Oncol 21: 673-678, 2003.
52. Tangpong J, Cole MP, Sultana R, Joshi G, Estus S, Vore M, St CW, Ratanachaiyavong S, St Clair DK, Butterfield DA. Adriamycin-induced, TNF-alpha-mediated central nervous system toxicity. Neurobiol Dis 23: 127-139, 2006.
53. Travers J, Dudgeon DJ, Amjadi K, McBride I, Dillon K, Laveneziana P, Ofir D, Webb KA, O'Donnell DE. Mechanisms of exertional dyspnea in patients with cancer. J Appl Physiol 104: 57-66, 2008.
54. Tukov FF, Luyendyk JP, Ganey PE, Roth RA. The role of tumor necrosis factor alpha in lipopolysaccharide/ranitidine-induced inflammatory liver injury. Toxicol Sci 100: 267-280, 2007.
55. 2+ pump function in rats. J Appl Physiol 103: 1921-1928, 2007.
56. Ujhazy P, Zaleskis G, Mihich E, Ehrke MJ, Berleth ES. Doxorubicin induces specific immune functions and cytokine expression in peritoneal cells. Cancer Immunol Immunother 52: 463-472, 2003.
57. Versteegh MI, Braun J, Voigt PG, Bosman DB, Stolk J, Rabe KF, Dion RA. Diaphragm plication in adult patients with diaphragm paralysis leads to long-term improvement of pulmonary function and level of dyspnea. Eur J Cardiothorac Surg 32: 449-456, 2007.
58. Viner RI, Williams TD, Schoneich C. Peroxynitrite modification of protein thiols: oxidation, nitrosylation, and S-glutathiolation of functionally important cysteine residue(s) in the sarcoplasmic reticulum Ca-ATPase. Biochemistry 38: 12408-12415, 1999.
59. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 10: 45-65, 2003.
60. Yende S, Waterer GW, Tolley EA, Newman AB, Bauer DC, Taaffe DR, Jensen R, Crapo R, Rubin S, Nevitt M, Simonsick EM, Satterfield S, Harris T, Kritchevsky SB. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax 61: 10-16, 2006.
61. Zhang J, Hawari FI, Shamburek RD, Adamik B, Kaler M, Islam A, Liao DW, Rouhani FN, Ingham M, Levine SJ. Circulating TNFR1 exosome-like vesicles partition with the LDL fraction of human plasma. Biochem Biophys Res Commun 366: 579-584, 2008.